en · de · es
selank-notes.peptides3626.com › Info › Background And Peptide Identity — Reference Sheet

Background And Peptide Identity — Reference Sheet

By Editorial Desk · published 2025-10-14 · last reviewed 2025-11-30 · Info

If you have been reading about blood-brain barrier and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Peptide Identity

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Mechanism and Evidence Status

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideModeled on tuftsin
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSeven residues
Approximate molecular massAround 750 DaDepends on counter-ion and hydration
Common formsLyophilized powderAlso described as aqueous solution
Primary origin of researchRussian laboratoriesMid-1990s onward

Proposed Mechanisms and Research Endpoints

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Related pages on this site

Administration, Testing and Availability

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Further detail

Statistical coupling energy is often systematically calculated between a fixed, perturbated position, and all other positions in an MSA. Continuing with the example MSA from the beginning of the section, consider a perturbation at position j where the amino distribution changes from 40% I, 40% H, 20% M to 100% I. If, in a subsequent subalignment, this changes the distribution at i from 60% V, 40% L to 90% V, 10% L, but does not change the distribution at position l, then there would be some amount of statistical coupling energy between i and j but none between l and j.

In February 2020, British law firm Stoke White appealed to the authorities in Britain, the U.S., and Turkey to arrest senior officials from the United Arab Emirates (UAE) for allegedly carrying out war crimes and torture in Yemen. The complaints were lodged under the provision of 'universal jurisdiction', wherein nations must probe breaches of the Geneva Convention for possible war crimes. In March 2020, Human Rights Watch accused Saudi military forces and Saudi-backed Yemeni forces of carrying out abuse of Yemeni civilians in the country's eastern province of al-Mahrah. They accused them arbitrarily arresting, torturing, and illegally transferring detainees to the kingdom of Saudi Arabia. The report documented 16 cases of arbitrary detention and five cases of detainees who had been transferred illegally to Saudi Arabia. According to a report from May 2020 by Yemeni human rights group Mwatana, since May 2016, more than 1,600 cases of arbitrary detentions, 770 forced disappearances, 344 cases of torture and at least 66 deaths in unofficial prisons have been documented. The report stated that Houthis were responsible for most abuses. It blamed them for 350 forced disappearances, 138 incidents of torture, and 27 deaths in detention, while UAE-backed forces, including the Southern Transitional Council, were responsible for 327 disappearances, 141 cases of torture, and 25 deaths in detention. The report blamed forces loyal to the Saudi-backed Yemeni government for 65 cases of torture and over 24 deaths.

=== Function === Calcium is an essential element needed in large quantities. The Ca2+ ion acts as an electrolyte and is vital to the health of the muscular, circulatory, and digestive systems; is indispensable to the building of bone in the form of hydroxyapatite; and supports synthesis and function of blood cells. For example, it regulates the contraction of muscles, nerve conduction, and the clotting of blood. As a result, intra- and extracellular calcium levels are tightly regulated by the body. Calcium can play this role because the Ca2+ ion forms stable coordination complexes with many organic compounds, especially proteins; it also forms compounds with a wide range of solubilities, enabling the formation of the skeleton.

Gueriguian, cited Rezulin's potential to harm the liver and the heart, and he questioned its viability in lowering blood sugar for patients with adult-onset diabetes, recommending against the drug's approval. After complaints from the drugmaker, Gueriguian was removed on November 4, 1996, and his review was purged by the FDA. Gueriguian and the company had a single meeting at which Gueriguian used "intemperate" language; the company said its objections were based on inappropriate remarks made by Gueriguian. Parke-Davis said at the advisory committee that the risk of liver toxicity was comparable to placebo and that additional data of other studies confirmed this. According to Peter Gøtzsche, when the company provided these additional data one week after approval, they showed a substantially greater risk for liver toxicity. The FDA approved the drug on January 29, 1997, and it appeared in pharmacies in late March. At the time, Dr. Solomon Sobel, a director at the FDA overseeing diabetes drugs, said in a New York Times interview that adverse effects of troglitazone appeared to be rare and relatively mild. Glaxo Wellcome received approval from the British Medicines Control Agency (MCA) to market troglitazone, as Romozin, in July 1997. After reports of sudden liver failure in patients receiving the drug, Parke-Davis and the FDA added warnings to the drug label requiring monthly monitoring of liver enzyme levels. Glaxo Wellcome removed troglitazone from the market in Britain on December 1, 1997.

Sources: en.wikipedia.org

Supporting material

Materials and samples from the original experiments remained in 2017 under the care of Miller's former student, Jeffrey Bada, a professor at the UCSD, Scripps Institution of Oceanography who also conducts origin of life research. As of 2013, the apparatus used to conduct the experiment was on display at the Denver Museum of Nature and Science.

== Personal life == In August 2009, it was reported that Lovett-Murray's home had been raided by police on 3 August. He was charged with possession of a drug of dependency, after the search found a single tablet of ecstasy at his home. However, on 11 December it was reported that the drug charge against him had been dismissed. On 22 May 2013, he was stabbed in a domestic incident by a girl's boyfriend and hospitalised. Lovett-Murray belongs to a sporting family and is the great-grandson of pastor Sir Douglas Nicholls, who played for Fitzroy Football Club. In addition, he is the cousin of former Essendon Football Club player Andrew Lovett.

====== The balkan route ====== The Balkan route remains the principal corridor for trafficking illegal opiates, primarily heroin, from Afghanistan to Western and Central Europe, with criminal networks-often highly organized and adaptable-leveraging both legal businesses and corruption to facilitate the smuggling, storage, and distribution of drugs. These groups generate enormous illicit profits, with the annual gross income from drug trafficking along the Balkan route estimated between $13.9 and $21.4 billion from 2019 to 2022, of which up to half is illegally moved across borders through complex financial flows that include shell companies, cryptocurrencies, and informal systems like hawala. The majority of these profits, around 90 percent, come from opiates, and the scale of this income rivals or exceeds the GDP of several countries along the route. The movement of these illicit funds not only sustains and expands drug trafficking operations but also undermines economic stability and governance in affected countries, making the Balkan route a persistent and multifaceted challenge for law enforcement and policymakers in the region.

The venom of snakes contains numerous proteins and peptide toxins that exhibit high affinity and specificity for a larger range of receptors. α-Bungarotoxin is a nicotinic receptor antagonist that binds irreversibly to the receptor, inhibiting the action of acetylcholine at the neuromuscular junctions. Nicotinic receptors are one of the two subtypes of cholinergic receptors, that respond to the neurotransmitter acetylcholine. Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels, being part of the ionotropic receptors. When a ligand is bound to it, it regulates excitability by controlling the ion flow during action potential during neurotransmission, primarily through the activation of voltage-gated ion channels upon depolarization of the plasma membrane. The depolarization is induced by an influx of cations, mainly that of sodium ions. For the overall modulation of cellular excitability, an influx of sodium ions and an efflux of potassium ions into the intracellular space is necessary. In the central and peripheral nervous system, α-bungarotoxin acts by inducing paralysis in skeletal muscles by binding to a subtype of nicotinic receptors α7. α-Neurotoxins are known as "curare-mimetic toxins" due to their similar effects to the arrow poison tubocurarine. A difference between α-neurotoxins and curare alkaloids is that they bind irreversibly and reversibly specifically. α-Neurotoxins block the action of acetylcholine (ACh) at the postsynaptic membrane by irreversibly inhibiting the ion flow.

== Early life == Gemma Clair Collins was born on 31 January 1981 at Oldchurch Hospital in Romford, East London. She is the daughter of Joan Collins (née Williams; 21 February 1955 — 29 July 2026), who worked as a part-time hairdresser, and Alan Collins, the director of Unisystems Freight, an import-export shipping company. She has an older brother named Russell, who is also a director of their father's company. Shortly after her birth, the family moved from a house in Collier Row and Collins was raised in Rise Park where she attended Rise Park Infant School. Collins described her childhood as being "filled with love" and said that although money was "tight", her father still managed to take them on family holidays and said she has "very happy memories" of her early years. Collins then went on to attend Frances Bardsley Academy for Girls. She enjoyed performing arts from a young age and attended dance lessons and stage school. At the age of 14, she began attending the Sylvia Young Theatre School and successfully auditioned for a part in The Sound of Music. Collins' mother was encouraging and said she knew that her daughter would one day become famous. Collins was bullied at school for being outgoing and confident, and so following the success of her father's business, her parents decided to move her to Raphael Independent School, a private school, for her final year of education. She left school at the age of 16 with a G in GCSE Maths.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is Selank?

Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.

Where was Selank developed?

It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.

Is Selank found in nature?

No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.

What mechanisms are proposed for Selank?

Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.

Network